Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company focused on developing AAV-mediated treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease. The company leverages pioneering science and a stepwise development approach to advance its pipeline of therapeutic candidates, aiming to address significant unmet medical needs.